Phase 2 study of RLS-0071 for the treatment of hypoxic-ischemic encephalopathy
Latest Information Update: 30 Jan 2024
At a glance
- Drugs RLS 0071 (Primary)
- Indications Cerebral ischaemia
- Focus Therapeutic Use
- 24 Jan 2024 According to a ReAlta Life Sciences media release, the company has received IND clearance form EMA for the treatment of hypoxic-ischemic encephalopathy (HIE).
- 13 Dec 2020 New trial record
- 03 Dec 2020 According to a ReAlta Life Sciences media release, the company intends to submit a clinical trial application (CTA) to the EMA.